Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integral Diagnostics Ltd. ( (AU:IDX) ) has provided an update.
Integral Diagnostics has disclosed a change in director Kevin Shaw’s interests, with Shaw acquiring 28,000 fully paid ordinary shares in the company via an on-market trade. The purchase, executed on 27 February 2026 at $2.43 per share, marks Shaw’s initial shareholding in the company and signals increased personal financial alignment with shareholders, though it does not alter any disclosed contractual interests or trading during a closed period.
The transaction underscores standard governance transparency requirements under ASX listing rules, ensuring investors are informed about directors’ equity positions. While the notice does not indicate any broader strategic shift, Shaw’s new stake may be interpreted by the market as a sign of confidence in Integral Diagnostics’ outlook and ongoing operations, potentially influencing stakeholder perception of board commitment and alignment.
The most recent analyst rating on (AU:IDX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited is an Australian healthcare company that provides diagnostic imaging services, focusing on radiology and related medical imaging for patients and referrers. The group operates through a network of clinics and imaging centres, supplying essential diagnostic support to healthcare providers across its markets.
Average Trading Volume: 706,778
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$909.4M
See more data about IDX stock on TipRanks’ Stock Analysis page.